Lynn Butler, DO
Internal Medicine · Elizabeth City, NCNPI 1700873486
Payments from drug & device makers
Across 80 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$224
- AbbVie$189
- Amgen$108
- Novartis$88
- Teva Pharmaceuticals USA, Inc.$76
- Pfizer$58
- plus $639 from 21 others
What the payments were for
- Food & beverage$1,382100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 14 | $224 |
| AbbVie(2 entities) | 11 | $189 |
| Amgen | 7 | $108 |
| Novartis | 5 | $88 |
| Teva Pharmaceuticals USA, Inc. | 6 | $76 |
| Pfizer | 4 | $58 |
| Lilly USA, LLC | 3 | $54 |
| Astellas Pharma US Inc | 3 | $52 |
| Exact Sciences | 2 | $49 |
| Boehringer Ingelheim | 3 | $48 |
| GSK | 3 | $48 |
| Johnson & Johnson | 2 | $39 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| AstraZeneca | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Irhythm Technologies, Inc. | 1 | $28 |
| Verona Pharma, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Eisai Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $22 |
| Corcept Therapeutics | 1 | $22 |
| Abbott | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Smith+Nephew | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
How this compares
$1,382 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 140 | $144,315 |
| JanuviaSitagliptin Phosphate | 98 | $109,494 |
| JardianceEmpagliflozin | 95 | $75,556 |
| XareltoRivaroxaban | 82 | $72,773 |
| OzempicSemaglutide | 44 | $65,174 |
| RybelsusSemaglutide | 27 | $47,898 |
| FarxigaDapagliflozin Propanediol | 24 | $28,319 |
| MounjaroTirzepatide | 17 | $24,012 |
| LinzessLinaclotide | 30 | $20,284 |
| TrulicityDulaglutide | 21 | $19,616 |
| Repatha SureclickEvolocumab | 23 | $17,776 |
| MyrbetriqMirabegron | 32 | $16,545 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $15,383 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $14,307 |
| Dexlansoprazole DrDexlansoprazole | 11 | $7,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $58 | $144,315140 claims |
| Novo NordiskOzempic, Rybelsus | $224 | $113,07271 claims |
| Boehringer IngelheimJardiance | $48 | $75,55695 claims |
| Johnson & JohnsonXarelto | $39 | $72,77382 claims |
| Lilly USA, LLCMounjaro, Trulicity | $54 | $43,62738 claims |
| AstraZenecaFarxiga, Symbicort | $29 | $34,65641 claims |
| AbbVieLinzess, Synthroid | $189 | $25,280104 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $16,54532 claims |
| GSKBreo Ellipta | $48 | $14,30725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Elizabeth City
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.